In a report released today, Brooks O’Neil from Lake Street maintained a Buy rating on Harrow Health (HROW – Research Report), with a price target of $20.00. The company’s shares closed yesterday at $12.07.
According to TipRanks, O’Neil is an analyst with an average return of -2.5% and a 42.24% success rate. O’Neil covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, Augmedix, and Alphatec Holdings.
Currently, the analyst consensus on Harrow Health is a Strong Buy with an average price target of $23.00.
HROW market cap is currently $427.1M and has a P/E ratio of -16.20.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HROW in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harrow Health (HROW) Company Description:
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
Read More on HROW:
